Business Wire

LIVANOVA

Share
LivaNova Recognizes International Epilepsy Day

Approximately two million people in Europe with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. VNS Therapy® , for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.

One in three people with epilepsy have the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.

“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, LivaNova’s president of the U.S. region and general manager of the neuromodulation franchise. “This treatment gap means that approximately two million individuals in Europe with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”

The goal of VNS Therapy is to prevent seizures before they start, and stop them if they do. People treated with VNS Therapy often experience shorter, less severe seizures, as well as fewer seizures. In addition, clinical trials have shown numerous quality of life improvements among people treated with VNS Therapy, including improved mood, alertness and memory. People with VNS Therapy also report gaining an average of 32 more working days per year, spend less time caring for health problems and worry less about seizures.

At six months old, Josh, a patient based in the United Kingdom, was tested for epilepsy and was confirmed as having febrile seizures. Over many years, he tried multiple types of anti-convulsant drugs.

“He would start on a new drug, it would be successful, we would see a really good improvement on Josh's seizures. But gradually, it was just like his seizures adapted to the drug sort of and basically, in the end, we almost ran out of options,” said Sharon, Josh’s mother.

At 16 years old, Josh received VNS Therapy. “It's had such an effect on Josh! He now is going to go to college. Josh is going to become a fully independent member of society and that's a great thing,” said Bob, Josh’s father.

VNS Therapy is a proven treatment designed to prevent seizures before they occur and stop them when they do. It is a unique treatment approach developed specifically for people with drug-resistant epilepsy, a condition that affects one in three people with epilepsy. For more information and to hear more patient stories, visit www.VNSTherapy.com .

INTENDED USE/INDICATION (outside the U.S.)

VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to seizure medications.

Safety information

Individual results may vary. Common side effects include hoarseness or changes in voice tone, prickling feeling in the skin, shortness of breath, sore throat and coughing. Visit http://www.livanova.cyberonics.com/eu/isi to view safety and full prescribing information.

About LivaNova

LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN.”

For more information, please visit www.LivaNova.com .

Contact:

LivaNova PLC Investor Relations and Media
Karen King, +1 281-228-7262
Vice President, Investor Relations & Corporate Communications
or
Deanna Wilke, +1 281-727-2764
Corporate External Communications Manager
corporate.communications@livanova.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Year-old European startup Maisa named alongside Google and Amazon in elite list of leading AI agent vendors in top global US research reports by Gartner3.7.2025 01:01:00 CEST | Press release

- First time a Spanish startup has made the list, thanks to its industry-first hallucination resistant ‘digital workers’ - AI startup is one of two European AI agent vendors in Gartner’s Hype Cycle report for Artificial Intelligence and Hype Cycle for the Future of Work lists Maisa, a rising star of enterprise AI, has been named by leading global research and advisory firm Gartner in its list of leading vendors for developing reliable AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702640749/en/ Maisa founders David Villalón and Manuel Romero Inclusion in Gartner’s 2025 Hype Cycle for AI and Hype Cycle for the Future of Work marks the first time a Spanish startup has been mentioned in these influential reports. The company, which is barely a year old and made its first raise of $5m+ from leading US investors last year, now finds itself named alongside global giants Amazon Web Services, Google, Salesforce and Lan

Hoffmann Green Announces a Historic Increase in Production Over the First Half of 2025, Already Outperforming the Annual Volumes Realized in 20242.7.2025 19:05:00 CEST | Press release

Record activity levels: +151% increase in production volumes in H1 2025 vs. H1 2024More than 130 construction sites supplied with more than 60,000 m³ of 0% clinker concrete delivered by 10,000 truck mixers across the countryAcceleration driven by a strengthened partnership network and the successful diversification of targeted marketsSolid outlook for the second half of 2025, in line with the strategic roadmap Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative clinker-free cements, today announces a strong acceleration of production over the first half of 2025, validating the relevance of its industrial and commercial business model. Production volumes reached 19,640 tonnes over the first half of 2025, compared with 7,833 tonnes in the first half of 2024, representing a 2.5-fold increase. This very strong leve

Institutional Real Estate, Inc. Announces Acquisition of U.K.-based Lyndon Publishing 2 Limited2.7.2025 18:44:00 CEST | Press release

Institutional Real Estate, Inc. (“IREI”) has completed its acquisition of the assets of London-based Lyndon Publishing 2 Ltd (“Lyndon Publishing”), which include The Property ChronicleandThe Green Chronicle.The former Lyndon Publishing 2 will now operate as a division of IREI. The Property Chronicle reaches a global audience of real estate investment professionals, researchers, and academics. Its sister publication, The Green Chronicle, is edited to address the interests and concerns of emerging young talent in these real estate professions. Both publications are produced as weekly news briefings filled with original content and contributed feature articles from industry thought and opinion leaders. In addition, The Property Chronicle is also published as a quarterly, illustrated full-color magazine available in both digital and print formats, while The Green Chronicleis published exclusively in digital format. Together, the two publications reach approximately 50,000 professionals acr

Sinopec Wins Technological Innovation Award at 2nd Sino-European Corporate ESG Best Practice Conference2.7.2025 18:21:00 CEST | Press release

China Petroleum & Chemical Corporation ("Sinopec", HKG: 0386) has won the "Best Scientific and Technological Innovation Practice" award at the 2nd Sino-European Corporate ESG Best Practice Conference (the "Conference") on June 26 in Stuttgart. Sinopec’s case submission of Breakthrough in Depth, Climb to New Heights — Empowering the Energy and Chemical Industry with Technological Innovation stood out among numerous entries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702387465/en/ Wang Tao, Sinopec representative, delivered a speech at the conference. The Conference reviews and awards the best ESG application cases in six areas of environmental protection, social responsibility, corporate management, scientific and technological innovation, education, and training to further enhance mutual understanding between Chinese and European businesses, facilitate bilateral economic and trade exchanges, and showcase China’s open,

Xsolla Releases Their Q2 2025 The State of Play Report: Mobile Gaming Is Projected to Hit $126B in 2025 Amid Global App Boom With In-Depth Analysis of Trends, Genres, and Monetization Strategies2.7.2025 18:00:00 CEST | Press release

Key Topics Include In-App Purchase Trends, Genre Performance, Player Demographics, D2C Strategy Adoption, and Hybrid Monetization Models Xsolla, a leading global video game commerce company, proudly announces the release of the Q2 2025 Edition of “The Xsolla Report: The State of Play.” This detailed report provides crucial insights, trends, and opportunities shaping the gaming landscape, empowering industry professionals to adapt and thrive in today’s rapidly changing market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702208715/en/ Graphic: Xsolla In 2024, global mobile app usage soared to an astonishing 4.2 trillion hours, an all-time high that powered a massive $150 billion consumer spending across mobile platforms. Mobile gaming is leading this charge, which accounted for more than half of that total. Despite a 6% dip in overall game downloads, falling to 49.6 billion, in-app purchase (IAP) revenue surged, indicati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye